It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Sjögren's syndrome (SjS) is characterized by lymphocytic infiltration of exocrine glands, i.e. autoimmune epithelitis. Lymphocytes are central in SjS pathogenesis, with B-cell hyperactivity mediated by T-cells. B-cells are main targets of Epstein-Barr virus (EBV) infection, a frequently-suggested trigger for SjS. We aimed to evaluate how the EBV infection modulates B and T-cell subsets in SjS, including as controls Rheumatoid arthritis patients (RA) and healthy participants (HC). SjS patients presented decreased CXCR5+T-cells, although IL21-secreting Tfh and Tfc cells were increased. Tfc were positively correlated with ESSDAI scores, suggesting their relevant role in SjS pathogenesis. As previously described, SjS patients showed expanded circulating naïve B-cell compartments. SjS patients had a higher incidence of EBV-EA-D-IgG+ antibodies, characteristic of recent EBV-infection/reactivation. SjS patients with past infection or recent infection/reactivation showed increased CXCR3+Th1 and CXCR3+Tfh1 cells compared to those without active infection. SjS patients with a recent infection/reactivation profile presented increased transitional B-cells compared to patients with past infection and increased plasmablasts, compared to those without infection. Our results suggest EBV-infection contributes to B and T-cell differentiation towards the effector phenotypes typical of SjS. Local lymphocyte activation at ectopic germinal centres, mediated by Tfh and Tfc, can be EBV-driven, perpetuating autoimmune epithelitis, which leads to gland destruction in SjS.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details









1 CHRC, Comprehensive Health Research Centre, Lisbon, Portugal; Universidade Nova de Lisboa, CEDOC, Chronic Diseases Research Center, Immunology, NOVA Medical School|FCM, Lisbon, Portugal (GRID:grid.10772.33) (ISNI:0000000121511713); Instituto Português de Reumatologia, Department of Rheumatology, Lisbon, Portugal (GRID:grid.10772.33); Hospital Cuf Descobertas, Department of Rheumatology, Lisbon, Portugal (GRID:grid.10772.33)
2 CHRC, Comprehensive Health Research Centre, Lisbon, Portugal (GRID:grid.10772.33); Universidade Nova de Lisboa, CEDOC, Chronic Diseases Research Center, Immunology, NOVA Medical School|FCM, Lisbon, Portugal (GRID:grid.10772.33) (ISNI:0000000121511713)
3 Hospital de Santo António Dos Capuchos, Department of Ophthalmology, Centro Hospitalar de Lisboa Central, Lisbon, Portugal (GRID:grid.413439.8)
4 Universidade Nova de Lisboa, CEDOC, Chronic Diseases Research Center, Immunology, NOVA Medical School|FCM, Lisbon, Portugal (GRID:grid.10772.33) (ISNI:0000000121511713)
5 Hospital de Santo António Dos Capuchos, Department of Ophthalmology, Centro Hospitalar de Lisboa Central, Lisbon, Portugal (GRID:grid.413439.8); Hospital Cuf Descobertas, Department of Ophthalmology, Lisbon, Portugal (GRID:grid.413439.8)
6 Instituto Português de Reumatologia, Department of Rheumatology, Lisbon, Portugal (GRID:grid.413439.8)
7 CHRC, Comprehensive Health Research Centre, Lisbon, Portugal (GRID:grid.413439.8); Universidade Nova de Lisboa, CEDOC, Chronic Diseases Research Center, Immunology, NOVA Medical School|FCM, Lisbon, Portugal (GRID:grid.10772.33) (ISNI:0000000121511713); Hospital Cuf Descobertas, Department of Rheumatology, Lisbon, Portugal (GRID:grid.10772.33); Hospital de Egas Moniz, Department of Rheumatology, Centro Hospitalar de Lisboa Ocidental, Lisbon, Portugal (GRID:grid.414462.1) (ISNI:0000 0001 1009 677X)
8 CHRC, Comprehensive Health Research Centre, Lisbon, Portugal (GRID:grid.414462.1); Universidade Nova de Lisboa, CEDOC, Chronic Diseases Research Center, Immunology, NOVA Medical School|FCM, Lisbon, Portugal (GRID:grid.10772.33) (ISNI:0000000121511713); Hospital da Luz, Department of Immunoalergy, Lisbon, Portugal (GRID:grid.414429.e) (ISNI:0000 0001 0163 5700)